Press Enter to search · Esc to close
A 56-week randomized trial finally tests what patients and surgeons have been doing off-script: adding liraglutide when the scale starts climbing again after bypass.
A major Herz review reaffirms that Mediterranean eating, structured movement and smoking cessation move the endpoints that matter — a useful corrective in the GLP-1 era.
Two 2025 preclinical studies hint at where this class is heading — longer-acting molecules, beta-cell-protective stacks, and the first real challengers to semaglutide's throne.
Native GLP-1 vanishes from your bloodstream in minutes. A fatty-acid tail turns it into a once-weekly shot — but the same trick that buys time also makes the drug harder to manufacture.
Two new studies reframe the conversation around metabolic health in later life — pointing to skeletal muscle, mitochondria, and medication choice as the quiet variables that matter.
A major European Heart Journal review reframes excess weight as a driver of the heart's biological aging itself. The implication: weight reduction may be less about preventing one bad day and more about extending healthy years.
Semaglutide and tirzepatide are reshaping body composition for millions of lifters and dieters. A cluster of 2025 reports is starting to map what happens when these drugs collide with surgery, scopes, and scans.
A multinational cohort sketches who's really starting GLP-1s for diabetes and kidney disease — and a new mouse study hints these drugs may rewire taste itself.
A new legal analysis warns that the same patent playbook that kept inhalers expensive for decades is now being run on GLP-1 drugs — just as millions of women are lining up for them.
GLP-1s rewrote metabolic medicine, but the syringe is still the weak link. New buccal devices and oral formulations are trying to close the gap — and the data is finally getting interesting.